What is the share price of Windlas Biotech Ltd (WINDLAS) today?
The share price of WINDLAS as on 18th September 2026 is ₹1109.45. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Windlas Biotech Ltd (WINDLAS) share?
The past returns of Windlas Biotech Ltd (WINDLAS) share are- Past 1 week: -0.94%
- Past 1 month: 18.85%
- Past 3 months: 37.37%
- Past 6 months: 51.69%
- Past 1 year: 16.17%
- Past 3 years: 209.69%
- Past 5 years: 195.81%
What are the peers or stocks similar to Windlas Biotech Ltd (WINDLAS)?
The peers or stocks similar to Windlas Biotech Ltd (WINDLAS) include:What is the dividend yield % of Windlas Biotech Ltd (WINDLAS) share?
The current dividend yield of Windlas Biotech Ltd (WINDLAS) is 0.58.What is the market cap of Windlas Biotech Ltd (WINDLAS) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Windlas Biotech Ltd (WINDLAS) is ₹2289.49 Cr as of 18th September 2026.What is the 52 week high and low of Windlas Biotech Ltd (WINDLAS) share?
The 52-week high of Windlas Biotech Ltd (WINDLAS) is ₹1181.90 and the 52-week low is ₹697.40.What is the PE and PB ratio of Windlas Biotech Ltd (WINDLAS) stock?
The P/E (price-to-earnings) ratio of Windlas Biotech Ltd (WINDLAS) is 34.45. The P/B (price-to-book) ratio is 3.94.Which sector does Windlas Biotech Ltd (WINDLAS) belong to?
Windlas Biotech Ltd (WINDLAS) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Windlas Biotech Ltd (WINDLAS) shares?
You can directly buy Windlas Biotech Ltd (WINDLAS) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Windlas Biotech Ltd
WINDLAS Share Price
NSE₹1,109.450.43% (-4.80)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
WINDLAS Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
WINDLAS Performance & Key Metrics
WINDLAS Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 34.47 | 3.94 | 0.58% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 47.20 | 5.92 | 0.48% |
WINDLAS Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
WINDLAS Company Profile
The company provides pharmaceutical development services. It provides contract manufacturing services for pharmaceutical industrialists and also focuses on product development and manufacturing capabilities in generic products.
SUNPHARMA
PE Ratio
38.40
38.40
1Y Return
11.45%
11.45%
Buy Reco %
93.33
93.33
TORNTPHARM
PE Ratio
85.10
85.10
1Y Return
35.67%
35.67%
Buy Reco %
81.48
81.48
ZYDUSLIFE
PE Ratio
22.96
22.96
1Y Return
10.70%
10.70%
Buy Reco %
55.56
55.56
CIPLA
PE Ratio
29.04
29.04
1Y Return
11.64%
11.64%
Buy Reco %
62.86
62.86
LAURUSLABS
PE Ratio
118.79
118.79
1Y Return
111.64%
111.64%
Buy Reco %
58.33
58.33
WINDLAS Sentiment Analysis
WINDLAS Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
WINDLAS Stock Summary · August 2026
Management framed the quarter as a strong start to FY27, with revenue reaching a record INR248 crores and rising 18% year on year, extending the company’s run to 14 consecutive quarters of growth. The tone was upbeat but measured, with management stressing that the business remains fundamentally volume-led as a CDMO, supported by customer expansion, deeper engagement and new product launches rather than pricing. Gross margin improvement was attributed to mix shift, better operational efficiency and a higher contribution from value-added products, even as lower Trade Generics and institutional volumes and volatile API pricing created offsets and made margin effects harder to isolate. Management also highlighted progress on growth platforms: Plant 6 has mechanically completed and is in customer validation, with full capacity expected by the end of H1 FY27, while injectables have largely returned to plan and exports remain a higher-gestation opportunity. The near-term path was described as one of continued incremental capacity additions, careful control of fixed costs and working capital, and a focus on converting current initiatives into revenue and cash flow.
WINDLAS Stock Growth Drivers
WINDLAS Stock Growth Drivers
8Record Revenue Growth and Operational Momentum
Windlas Biotech delivered its highest-ever quarterly revenue of INR248 crores in Q1 FY27, up 18%
Margin Expansion and Profitability Improvement
Profitability improved meaningfully alongside revenue growth, with adjusted EBITDA rising 26% year on year to
WINDLAS Stock Challenges
WINDLAS Stock Challenges
5Trade Generics and Institutional Revenue Loss from Codeine Exit
The Trade Generics and institutional business remains materially weaker after the removal of codeine-based and
Weak and Uncertain Industry Volume Growth
Industry volume growth has been a negative backdrop for the business, with management stating that
WINDLAS Forecast
WINDLAS Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
WINDLAS
WINDLAS
Income
Balance Sheet
Cash Flow
Quarterly Normal View
WINDLAS Income Statement
WINDLAS Income Statement
Quarterly Normal View
| Quarter | dec 2023 | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 165.38 | 175.73 | 179.29 | 191.84 | 199.13 | 207.64 | 215.33 | 226.04 | 237.67 | 242.85 | ||||||||||
Operating & Other expenses | 141.88 | 149.28 | 154.27 | 163.95 | 170.39 | 177.16 | 183.57 | 193.84 | 208.73 | 213.21 | ||||||||||
EBITDA | 23.50 | 26.45 | 25.02 | 27.89 | 28.74 | 30.48 | 31.76 | 32.20 | 28.94 | 29.64 | ||||||||||
| Depreciation/Amortization | 3.39 | 3.54 | 6.21 | 6.50 | 6.94 | 8.34 | 7.45 | 7.60 | 7.70 | 8.00 | ||||||||||
| PBIT | 20.11 | 22.91 | 18.81 | 21.39 | 21.80 | 22.14 | 24.31 | 24.60 | 21.24 | 21.64 | ||||||||||
| Interest & Other Items | 0.31 | 0.28 | 0.49 | 1.10 | 1.46 | 1.33 | 1.06 | 1.02 | 1.28 | 1.48 | ||||||||||
| PBT | 19.80 | 22.63 | 18.32 | 20.29 | 20.34 | 20.81 | 23.25 | 23.58 | 19.96 | 20.16 | ||||||||||
| Taxes & Other Items | 4.71 | 5.64 | 4.83 | 4.63 | 4.76 | 4.55 | 5.59 | 5.79 | 4.97 | 4.18 | ||||||||||
| Net Income | 15.09 | 16.99 | 13.49 | 15.66 | 15.58 | 16.26 | 17.66 | 17.79 | 14.99 | 15.98 | ||||||||||
| EPS | 7.26 | 8.17 | 6.47 | 7.49 | 7.45 | 7.77 | 8.43 | 8.48 | 7.12 | 7.58 |
WINDLAS Company Updates
FY 2027FY 2027
Investor Presentation
Aug 10PDF
WINDLAS Stock Peers
WINDLAS Past Performance & Peer Comparison
WINDLAS Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Windlas Biotech Ltd | 34.45 | 3.94 | 0.58% |
| Sun Pharmaceutical Industries Ltd | 38.40 | 5.26 | 0.87% |
| Torrent Pharmaceuticals Ltd | 85.10 | 10.47 | 0.70% |
| Zydus Lifesciences Ltd | 22.96 | 3.91 | 0.09% |
WINDLAS Stock Price Comparison
Compare WINDLAS with any stock or ETFCompare WINDLAS with any stock or ETF
WINDLAS
WINDLAS Holdings
WINDLAS Shareholdings
WINDLAS Promoter Holdings Trend
WINDLAS Promoter Holdings Trend
Increased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has increased by 1.32%
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
WINDLAS Institutional Holdings Trend
WINDLAS Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Increased Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has increased by 1.45%
WINDLAS Shareholding Pattern
WINDLAS Shareholding Pattern
WINDLAS Shareholding History
WINDLAS Shareholding History
Foreign Institutions
Mutual Funds Invested in WINDLAS
Mutual Funds Invested in WINDLAS
No mutual funds holding trends are available
Top 5 Mutual Funds holding Windlas Biotech Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.7063% | Percentage of the fund’s portfolio invested in the stock 0.57% | Change in the portfolio weight of the stock over the last 3 months -0.20% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 37/41 (-5) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.1686% | Percentage of the fund’s portfolio invested in the stock 0.08% | Change in the portfolio weight of the stock over the last 3 months -0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 193/277 (0) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.8095% | Percentage of the fund’s portfolio invested in the stock 1.28% | Change in the portfolio weight of the stock over the last 3 months 0.06% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 32/46 (+1) |
Compare 3-month MF holding change on Screener
smallcases containing WINDLAS stock
smallcases containing WINDLAS stock
Looks like this stock is not in any smallcase yet.
WINDLAS Events
WINDLAS Events
WINDLAS Dividend Trend
Increasing Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
WINDLAS has increased dividends consistently over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.58%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹5.81 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
WINDLAS Dividend Trend
Increasing Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
WINDLAS has increased dividends consistently over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.58%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹5.81 every year
WINDLAS Upcoming Dividends
WINDLAS Upcoming Dividends
No upcoming dividends are available
WINDLAS Past Dividends
WINDLAS Past Dividends
Cash Dividend
Ex DateEx DateJul 16, 2026
Final
Final | Div/Share: ₹6.30
Dividend/Share
₹6.30
Ex DateEx Date
Jul 16, 2026
Cash Dividend
Ex DateEx DateJul 21, 2025
Final
Final | Div/Share: ₹5.80
Dividend/Share
₹5.80
Ex DateEx Date
Jul 21, 2025
Cash Dividend
Ex DateEx DateSep 17, 2024
Final
Final | Div/Share: ₹5.50
Dividend/Share
₹5.50
Ex DateEx Date
Sep 17, 2024
Cash Dividend
Ex DateEx DateSep 5, 2023
Final
Final | Div/Share: ₹4.00
Dividend/Share
₹4.00
Ex DateEx Date
Sep 5, 2023
Cash Dividend
Ex DateEx DateSep 9, 2022
Final
Final | Div/Share: ₹3.50
Dividend/Share
₹3.50
Ex DateEx Date
Sep 9, 2022
WINDLAS Stock News & Opinions
WINDLAS Stock News & Opinions
Articles & Videos
Corporate
Corporate
Windlas Biotech to review quarterly results at board meeting on August 10, 2026Windlas Biotech Limited will hold a board meeting on August 10, 2026, to consider and approve the unaudited standalone financial results for the quarter ended June 30, 2026, according to a regulatory filing. The company’s trading window has been closed since July 1, 2026, and will reopen 48 hours after the financial results are declared.
1 month agoCapital Market - Live
Corporate
Corporate
Windlas Biotech to conduct AGMWindlas Biotech announced that the 25th Annual General Meeting(AGM) of the company will be held on 23 July 2026.
2 months agoCapital Market - Live
Corporate
Corporate
Board of Windlas Biotech recommends final dividendWindlas Biotech announced that the Board of Directors of the Company at its meeting held on 21 May 2026, inter alia, have recommended the final dividend of Rs 6.3 per equity Share (i.e. 126%) , subject to the approval of the shareholders.
4 months agoCapital Market - Live
Earnings
Earnings
Windlas Biotech consolidated net profit declines 1.78% in the March 2026 quarterNet profit of Windlas Biotech declined 1.78% to Rs 15.99 crore in the quarter ended March 2026 as against Rs 16.28 crore during the previous quarter ended March 2025. Sales rose 17.66% to Rs 238.50 crore in the quarter ended March 2026 as against Rs 202.71 crore during the previous quarter ended March 2025. For the full year,net profit rose 8.97% to Rs 66.46 crore in the year ended March 2026 as against Rs 60.99 crore during the previous year ended March 2025. Sales rose 18.98% to Rs 904.09 crore in the year ended March 2026 as against Rs 759.88 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales238.50202.71 18 904.09759.88 19 OPM %10.6012.60 -11.5912.38 - PBDT28.1629.16 -3 117.72107.74 9 PBT20.1620.82 -3 86.9879.76 9 NP15.9916.28 -2 66.4660.99 9 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Corporate
Windlas Biotech to conduct board meetingWindlas Biotech will hold a meeting of the Board of Directors of the Company on 21 May 2026.
4 months agoCapital Market - Live
Corporate
Corporate
Windlas Biotech fixes record date for buyback of sharesWindlas Biotech has fixed 24 April 2026 as record date for the purpose of ascertaining the eligibility of shareholders for buyback of equity shares.
5 months agoCapital Market - Live
Corporate
Corporate
Board of Windlas Biotech approves buyback of shares of Rs 47 crThe board of Windlas Biotech at its meeting held on 17 April 2026 has approved buyback of up to 4,70,000 fully paid up equity shares of the company (representing 2.23% of the paid up equity share capital) at a price of Rs 1,000 per equity share for an aggregate amount not exceeding Rs 47 crore.
5 months agoCapital Market - Live
Corporate
Corporate
Windlas Biotech to consider BuybackWindlas Biotech will hold a meeting of the Board of Directors of the Company on 17 April 2026.
5 months agoCapital Market - Live
Corporate
Corporate
Windlas Biotech alltos 28,990 equity shares under ESOSWindlas Biotech has allotted 28,990 equity shares under ESOS on 13 March 2026. Powered by Capital Market - Live
6 months agoCapital Market - Live
Earnings
Earnings
Windlas Biotech consolidated net profit declines 3.72% in the December 2025 quarterNet profit of Windlas Biotech declined 3.72% to Rs 15.00 crore in the quarter ended December 2025 as against Rs 15.58 crore during the previous quarter ended December 2024. Sales rose 19.53% to Rs 233.10 crore in the quarter ended December 2025 as against Rs 195.02 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales233.10195.02 20 OPM %10.4612.63 - PBDT27.6727.28 1 PBT19.9720.34 -2 NP15.0015.58 -4 Powered by Capital Market - Live
7 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 16.14%, vs industry avg of 11.76%
Over the last 5 years, market share increased from 0.15% to 0.18%
Over the last 5 years, net income has grown at a yearly rate of 33.25%, vs industry avg of 10.45%